Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
1998 1
1999 13
2000 5
2001 6
2002 7
2003 8
2004 17
2005 12
2006 13
2007 14
2008 7
2009 5
2010 8
2011 7
2012 10
2013 12
2014 4
2015 10
2016 11
2017 3
2018 10
2019 15
2020 9
2021 8
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS. Burmester GR, et al. Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18. Lancet. 2018. PMID: 29908669 Clinical Trial.
We enrolled patients aged 18 years or older with active rheumatoid arthritis for 3 months or longer, who had received csDMARDs for at least 3 months with a stable dose for at least 4 weeks before study entry, and had an inadequate response to at least one of the following csDMARD …
We enrolled patients aged 18 years or older with active rheumatoid arthritis for 3 months or longer, who had received csDMARDs for at least …
Comparative Study of Intravenous Immunoglobulin and Leflunomide Combination Therapy With Intravenous Immunoglobulin Single Therapy in Kidney Transplant Patients With BK Virus Infection: Single-Center Clinical Trial.
Rasaei N, Malekmakan L, Gholamabbas G, Abdizadeh P. Rasaei N, et al. Exp Clin Transplant. 2023 Oct;21(10):814-819. doi: 10.6002/ect.2023.0071. Exp Clin Transplant. 2023. PMID: 37965956 Free article. Clinical Trial.
Here, we compared the combination of intravenous immunoglobulin and leflunomide versus intravenous immunoglobulin to treat BK virus nephropathy after renal transplant. ...CONCLUSIONS: Although BK viral load decreased significantly in both groups, there was a significant di …
Here, we compared the combination of intravenous immunoglobulin and leflunomide versus intravenous immunoglobulin to treat BK virus n …
Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up.
Fu Q, Wu C, Dai M, Wang S, Xu J, Dai L, Li Z, He L, Zhu X, Sun L, Lu L, Bao C. Fu Q, et al. Ann Rheum Dis. 2022 Nov;81(11):1549-1555. doi: 10.1136/ard-2022-222486. Epub 2022 Jul 4. Ann Rheum Dis. 2022. PMID: 35788493 Free PMC article. Clinical Trial.
Extrarenal flare occurred in two patients from the azathioprine group and one patient from the leflunomide group. The incidence of adverse events was similar in the 2 groups: leflunomide 56.5% and azathioprine 58.9%. ...Leflunomide may provide a new candidate …
Extrarenal flare occurred in two patients from the azathioprine group and one patient from the leflunomide group. The incidence of ad …
Combination of Methotrexate and Leflunomide Is Efficient and Safe for 60 Patients with Rheumatoid Arthritis.
Chen F, Wang Y, Wang L, Du H, He S. Chen F, et al. Comput Math Methods Med. 2022 Oct 3;2022:6829358. doi: 10.1155/2022/6829358. eCollection 2022. Comput Math Methods Med. 2022. Retraction in: Comput Math Methods Med. 2023 Nov 29;2023:9801924. doi: 10.1155/2023/9801924. PMID: 36226244 Free PMC article. Retracted. Clinical Trial.
The present work is aimed at exploring the clinical efficacy and safety of methotrexate (MTX) and leflunomide (LEF) combination therapy for rheumatoid arthritis. From June 2019 to June 2021, a total of 120 individuals with rheumatoid arthritis received a diagnosis. ...
The present work is aimed at exploring the clinical efficacy and safety of methotrexate (MTX) and leflunomide (LEF) combination thera …
Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial.
Belani PJ, Kavadichanda CG, Negi VS. Belani PJ, et al. Rheumatol Int. 2022 May;42(5):771-782. doi: 10.1007/s00296-021-04994-1. Epub 2021 Sep 29. Rheumatol Int. 2022. PMID: 34586472 Clinical Trial.
Secondary endpoints were improvement in DAS28, functional outcome and adverse events at 24 weeks. 136 eligible patients were randomized to either Leflunomide or Sulfasalazine group (68 in each group).63 and 59 patients in Leflunomide and 66 and 61 patients in Sulfas …
Secondary endpoints were improvement in DAS28, functional outcome and adverse events at 24 weeks. 136 eligible patients were randomized to e …
Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial.
Wang Y, Zhao Z, Gao D, Wang H, Liao S, Dong C, Luo G, Ji X, Li Y, Wang X, Zhao Y, Li K, Zhang J, Jin J, Zhang Y, Zhu J, Zhang J, Huang F. Wang Y, et al. Semin Arthritis Rheum. 2020 Dec;50(6):1513-1520. doi: 10.1016/j.semarthrit.2020.01.010. Epub 2020 Feb 3. Semin Arthritis Rheum. 2020. PMID: 32113839 Clinical Trial.
OBJECTIVES: To evaluate the efficacy and safety of leflunomide (LEF) and glucocorticoids (GCs) combination therapy compared with GCs monotherapy in preventing relapse of IgG4-related disease (IgG4-RD). ...
OBJECTIVES: To evaluate the efficacy and safety of leflunomide (LEF) and glucocorticoids (GCs) combination therapy compared with GCs …
Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial.
Huang RY, Pan HD, Wu JQ, Zhou H, Li ZG, Qiu P, Zhou YY, Chen XM, Xie ZX, Xiao Y, Huang QC, Liu L. Huang RY, et al. Phytomedicine. 2019 Apr;57:403-410. doi: 10.1016/j.phymed.2018.12.030. Epub 2018 Dec 25. Phytomedicine. 2019. PMID: 30851515 Free article. Clinical Trial.
METHODS: Patients were randomly assigned at a 3:2 ratio to receive MTX combined with sinomenine (SIN) at a dose of 120 mg twice daily, or leflunomide (LEF) at a dose of 20 mg once daily. Efficacy and safety were assessed at weeks 4, 12 and 24. ...
METHODS: Patients were randomly assigned at a 3:2 ratio to receive MTX combined with sinomenine (SIN) at a dose of 120 mg twice daily, or …
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study).
Behrens F, Koehm M, Rossmanith T, Alten R, Aringer M, Backhaus M, Burmester GR, Feist E, Herrmann E, Kellner H, Krueger K, Lehn A, Müller-Ladner U, Rubbert-Roth A, Tony HP, Wassenberg S, Burkhardt H. Behrens F, et al. Rheumatology (Oxford). 2021 Nov 3;60(11):5318-5328. doi: 10.1093/rheumatology/keab153. Rheumatology (Oxford). 2021. PMID: 33738492 Free PMC article. Clinical Trial.
Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial.
Wijesinghe H, Galappatthy P, de Silva R, Seneviratne SL, Saravanamuttu U, Udagama P, Hart M, Kelleher P, Senerath U, Fernandopulle R, Weerasekera LP, Wijayaratne LS. Wijesinghe H, et al. BMC Musculoskelet Disord. 2017 Jul 19;18(1):310. doi: 10.1186/s12891-017-1673-3. BMC Musculoskelet Disord. 2017. PMID: 28724365 Free PMC article. Clinical Trial.
Efficacy of low dose rituximab in rheumatoid arthritis (RA) refractory to first-line non-biologic Disease Modifying Anti Rheumatic Drugs (DMARDs), compared to leflunomide is unknown. In a tertiary care referral setting, we conducted a randomized, double blind controlled cl …
Efficacy of low dose rituximab in rheumatoid arthritis (RA) refractory to first-line non-biologic Disease Modifying Anti Rheumatic Drugs (DM …
Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial.
Wu J, Duan SW, Sun XF, Li WG, Wang YP, Liu WH, Zhang JR, Lun LD, Li XM, Zhou CH, Li JJ, Liu SW, Xie YS, Cai GY, Ma L, Huang W, Wu H, Jia Q, Chen XM. Wu J, et al. Chin Med J (Engl). 2016 Aug 20;129(16):1894-903. doi: 10.4103/0366-6999.187848. Chin Med J (Engl). 2016. PMID: 27503012 Free PMC article. Clinical Trial.
BACKGROUND: The efficacy and safety of telmisartan combined with clopidogrel, leflunomide, or both drugs for immunoglobulin A nephropathy (IgAN) are unclear. ...After a 4-week telmisartan (80 mg/d) wash-in, 400 patients continuing on 80 mg/d telmisartan were randomly assig …
BACKGROUND: The efficacy and safety of telmisartan combined with clopidogrel, leflunomide, or both drugs for immunoglobulin A nephrop …
205 results